Noel G Morgan

List of Publications by Year in Descending Order

209 papers	7,999 citations	49 h-index	80 g-index
213 ext. papers	9,024 ext. citations	6 avg, IF	5.88 L-index

#	Paper	IF	Citations
209	Differential routing and disposition of the long-chain saturated fatty acid palmitate in rodent vs human beta-cells.. *Nutrition and Diabetes*, **2022**, 12, 22	4.7	1
208	Temporal regulation of interferon signalling in human EndoC-βH1 cells.. *Journal of Molecular Endocrinology*, **2022**, 69, 299-313	4.5	0
207	HLA Class I Upregulation and Antiviral Immune Responses in Graves Disease. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e1763-e1774	5.6	2
206	Expression of CD47 in the pancreatic β cells of people with recent-onset type 1 diabetes varies according to disease endotype. *Diabetic Medicine*, **2021**, 38, e14724	3.5	1
205	Identification and characterisation of tertiary lymphoid organs in human type 1 diabetes. *Diabetologia*, **2021**, 64, 1626-1641	10.3	2
204	Altered β Cell Prohormone Processing and Secretion in Type 1 Diabetes. *Diabetes*, **2021**, 70, 1038-1050	0.9	4
203	Long-chain saturated fatty acid species are not toxic to human pancreatic β cells and may offer protection against pro-inflammatory cytokine induced β cell death. *Nutrition and Metabolism*, **2021**, 18, 9	4.6	3
202	Footprints of Immune Cells in the Pancreas in Type 1 Diabetes; to "B" or Not to "B": Is That Still the Question?. *Frontiers in Endocrinology*, **2021**, 12, 617437	5.7	1
201	Investigation of the utility of the 1.1B4 cell as a model human beta cell line for study of persistent enteroviral infection. *Scientific Reports*, **2021**, 11, 15624	4.9	1
200	Vitamin-D-Binding Protein Contributes to the Maintenance of β Cell Function and Glucagon Secretion. *Cell Reports*, **2020**, 31, 107761	10.6	5
199	Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. *Diabetologia*, **2020**, 63, 1258-1267	10.3	40
198	Reduced Expression of the Co-regulator TLE1 in Type 2 Diabetes Is Associated with Increased Islet β Cell Number. *Endocrinology*, **2020**, 161,	4.8	5
197	An integrated multi-omics approach identifies the landscape of interferon-β mediated responses of human pancreatic beta cells. *Nature Communications*, **2020**, 11, 2584	17.4	41
196	Upregulation of HLA Class I and Antiviral Tissue Responses in Hashimoto's Thyroiditis. *Thyroid*, **2020**, 30, 432-442	6.2	6
195	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. *Diabetes Care*, **2020**, 43, 5-12	14.6	111
194	In Situ Analysis Reveals That CFTR Is Expressed in Only a Small Minority of β Cells in Normal Adult Human Pancreas. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	13
193	Type 1 Diabetes: Interferons and the Aftermath of Pancreatic Beta-Cell Enteroviral Infection. *Microorganisms*, **2020**, 8,	4.9	9

192	The inducible 5i proteasome subunit contributes to proinsulin degradation in GRP94-deficient Ecells and is overexpressed in type 2 diabetes pancreatic islets. *American Journal of Physiology - Endocrinology and Metabolism*, **2020**, 318, E892-E900	6	3
191	Cellular stressors may alter islet hormone cell proportions by moderation of alternative splicing patterns. *Human Molecular Genetics*, **2019**, 28, 2763-2774	5.6	8
190	Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]. *Diabetologia*, **2019**, 62, 1100-1103	10.3	3
189	HLA Class II Antigen Processing and Presentation Pathway Components Demonstrated by Transcriptome and Protein Analyses of Islet ECells From Donors With Type 1 Diabetes. *Diabetes*, **2019**, 68, 988-1001	0.9	52
188	Offspring of Mice Exposed to a Low-Protein Diet in Utero Demonstrate Changes in mTOR Signaling in Pancreatic Islets of Langerhans, Associated with Altered Glucagon and Insulin Expression and a Lower ECell Mass. *Nutrients*, **2019**, 11,	6.7	10
187	Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. *Diabetologia*, **2019**, 62, 744-753	10.3	40
186	How, When, and Where Do Human ECells Regenerate?. *Current Diabetes Reports*, **2019**, 19, 48	5.6	14
185	Differential effects of saturated and unsaturated fatty acids on autophagy in pancreatic Ecells. *Journal of Molecular Endocrinology*, **2019**, 63, 285-296	4.5	3
184	Evidence that a STAT3 Mutation Causing Hyper IgE Syndrome Leads to Repression of Transcriptional Activity. *Case Reports in Immunology*, **2019**, 2019, 1869524	1.9	1
183	The transcription factor STAT6 plays a critical role in promoting beta cell viability and is depleted in islets of individuals with type 1 diabetes. *Diabetologia*, **2019**, 62, 87-98	10.3	9
182	Abnormal islet sphingolipid metabolism in type 1 diabetes. *Diabetologia*, **2018**, 61, 1650-1661	10.3	30
181	Molecular Pathways for Immune Recognition of Preproinsulin Signal Peptide in Type 1 Diabetes. *Diabetes*, **2018**, 67, 687-696	0.9	22
180	Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention. *Current Opinion in Pharmacology*, **2018**, 43, 11-19	5.1	34
179	Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. *Diabetologia*, **2018**, 61, 2344-2355	10.3	31
178	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. *Diabetes Care*, **2018**, 41, 1486-1492	14.6	54
177	Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. *JCI Insight*, **2018**, 3,	9.9	50
176	A novel de novo activating mutation in STAT3 identified in a patient with common variable immunodeficiency (CVID). *Clinical Immunology*, **2018**, 187, 132-136	9	13
175	Fifty years of pancreatic islet pathology in human type 1 diabetes: insights gained and progress made. *Diabetologia*, **2018**, 61, 2499-2506	10.3	38

174	PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-□ and-□via IRF1 induction. *EBioMedicine*, **2018**, 36, 367-375	8.8	86
173	Re-addressing the 2013 consensus guidelines for the diagnosis of insulitis in human type 1 diabetes: is change necessary?. *Diabetologia*, **2017**, 60, 753-755	10.3	6
172	Germinal centre frequency is decreased in pancreatic lymph nodes from individuals with recent-onset type 1 diabetes. *Diabetologia*, **2017**, 60, 1294-1303	10.3	8
171	An Activating STAT3 Mutation Causes Neonatal Diabetes through Premature Induction of Pancreatic Differentiation. *Cell Reports*, **2017**, 19, 281-294	10.6	67
170	Bringing the human pancreas into focus: new paradigms for the understanding of Type 1 diabetes. *Diabetic Medicine*, **2017**, 34, 879-886	3.5	9
169	Siglec-7 restores □cell function and survival and reduces inflammation in pancreatic islets from patients with diabetes. *Scientific Reports*, **2017**, 7, 45319	4.9	22
168	Detection and localization of viral infection in the pancreas of patients with type 1 diabetes using short fluorescently-labelled oligonucleotide probes. *Oncotarget*, **2017**, 8, 12620-12636	3.3	19
167	An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in □Cell Protection. *ACS Chemical Biology*, **2016**, 11, 363-74	4.9	58
166	Differential Insulitic Profiles Determine the Extent of □Cell Destruction and the Age at Onset of Type 1 Diabetes. *Diabetes*, **2016**, 65, 1362-9	0.9	162
165	Relative sensitivity of immunohistochemistry, multiple reaction monitoring mass spectrometry, in situ hybridization and PCR to detect Coxsackievirus B1 in A549 cells. *Journal of Clinical Virology*, **2016**, 77, 21-8	14.5	18
164	Spatiotemporal Dynamics of Insulitis in Human Type 1 Diabetes. *Frontiers in Physiology*, **2016**, 7, 633	4.6	10
163	Changing perspectives on the progression of type 1 diabetes. *Practical Diabetes*, **2016**, 33, 118-120	0.7	1
162	Targeting surface voids to counter membrane disorders in lipointoxication-related diseases. *Journal of Cell Science*, **2016**, 129, 2368-81	5.3	5
161	Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. *Diabetologia* , **2016**, 59, 2448-2458	10.3	145
160	The subcellular distribution of cyclin-D1 and cyclin-D3 within human islet cells varies according to the status of the pancreas donor. *Diabetologia*, **2015**, 58, 2056-63	10.3	4
159	Differential cell autonomous responses determine the outcome of coxsackievirus infections in murine pancreatic □and □cells. *ELife*, **2015**, 4, e06990	8.9	37
158	Detection of a low-grade enteroviral infection in the islets of langerhans of living patients newly diagnosed with type 1 diabetes. *Diabetes*, **2015**, 64, 1682-7	0.9	196
157	Pancreatic pathology in type 1 diabetes mellitus. *Endocrine Pathology*, **2014**, 25, 80-92	4.2	53

156	Detection of enterovirus in the islet cells of patients with type 1 diabetes: what do we learn from immunohistochemistry? Reply to Hansson SF, Korsgren S, Pontén F et al [letter]. *Diabetologia*, **2014**, 57, 647-9	10.3	11
155	Infection of human islets of Langerhans with two strains of Coxsackie B virus serotype 1: assessment of virus replication, degree of cell death and induction of genes involved in the innate immunity pathway. *Journal of Medical Virology*, **2014**, 86, 1402-11	19.7	35
154	Enteroviruses as causative agents in type 1 diabetes: loose ends or lost cause?. *Trends in Endocrinology and Metabolism*, **2014**, 25, 611-9	8.8	48
153	Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. *Diabetes*, **2014**, 63, 3835-45	0.9	144
152	Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. *Nature Genetics*, **2014**, 46, 812-814	36.3	328
151	GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans. *Diabetologia*, **2014**, 57, 1182-91	10.3	98
150	The beneficial effects of n-3 polyunsaturated fatty acids on diet induced obesity and impaired glucose control do not require Gpr120. *PLoS ONE*, **2014**, 9, e114942	3.7	51
149	The impact of anti-inflammatory cytokines on the pancreatic β-cell. *Islets*, **2014**, 6, e950547	2	46
148	Islet inflammation in human type 1 diabetes mellitus. *IUBMB Life*, **2014**, 66, 723-34	4.7	51
147	Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas. *Diabetologia*, **2014**, 57, 392-401	10.3	32
146	Viruses in the Human Pancreas **2013**, 167-175		1
145	Sirtuin 3 regulates mouse pancreatic beta cell function and is suppressed in pancreatic islets isolated from human type 2 diabetic patients. *Diabetologia*, **2013**, 56, 1068-77	10.3	85
144	Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. *Diabetologia*, **2013**, 56, 185-93	10.3	99
143	The diagnosis of insulitis in human type 1 diabetes. *Diabetologia*, **2013**, 56, 2541-3	10.3	130
142	Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets. *Journal of Virology*, **2013**, 87, 7646-54	6.6	34
141	Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells. *Islets*, **2013**, 5, 95-105	2	32
140	The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119. *British Journal of Pharmacology*, **2012**, 165, 2758-70	8.6	18
139	Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. *Diabetologia*, **2012**, 55, 2417-20	10.3	159

138	Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. *Diabetologia*, **2012**, 55, 2421-31	10.3	68
137	Pharmacological characterization of the cytoprotective effects of polyunsaturated fatty acids in insulin-secreting BRIN-BD11 cells. *British Journal of Pharmacology*, **2011**, 162, 1340-50	8.6	12
136	Structure-activity relationships influencing lipid-induced changes in eIF2 phosphorylation and cell viability in BRIN-BD11 cells. *FEBS Letters*, **2011**, 585, 2243-8	3.8	7
135	Immunohistochemical analysis of the relationship between islet cell proliferation and the production of the enteroviral capsid protein, VP1, in the islets of patients with recent-onset type 1 diabetes. *Diabetologia*, **2011**, 54, 2417-20	10.3	48
134	Immunopathology of the human pancreas in type-I diabetes. *Seminars in Immunopathology*, **2011**, 33, 9-21	12	66
133	Down-regulation of proliferation does not affect the secretory function of transformed cell lines regardless of their anatomical configuration. *Islets*, **2011**, 3, 80-8	2	9
132	Arachidonic acid actions on functional integrity and attenuation of the negative effects of palmitic acid in a clonal pancreatic cell line. *Clinical Science*, **2011**, 120, 195-206	6.5	38
131	Conditional expression of the FTO gene product in rat INS-1 cells reveals its rapid turnover and a role in the profile of glucose-induced insulin secretion. *Clinical Science*, **2011**, 120, 403-13	6.5	16
130	Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 3105-10	11.5	149
129	Expression and functional roles of guanylate cyclase isoforms in BRIN-BD11 cells. *Islets*, **2010**, 2, 374-82	2	9
128	Use of antisera directed against dsRNA to detect viral infections in formalin-fixed paraffin-embedded tissue. *Journal of Clinical Virology*, **2010**, 49, 180-5	14.5	22
127	Unsaturated fatty acids as cytoprotective agents in the pancreatic beta-cell. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2010**, 82, 231-6	2.8	40
126	Combining enteral with parenteral nutrition to improve postoperative glucose control. *British Journal of Nutrition*, **2010**, 103, 1635-41	3.6	37
125	The significance of GPR119 agonists as a future treatment for type 2 diabetes. *Drug News and Perspectives*, **2010**, 23, 418-24		22
124	Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. *Diabetologia*, **2010**, 53, 2020-8	10.3	72
123	Human and rodent pancreatic beta-cells express IL-4 receptors and IL-4 protects against beta-cell apoptosis by activation of the PI3K and JAK/STAT pathways. *Bioscience Reports*, **2009**, 30, 169-75	4.1	20
122	G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell. *Biochemical Pharmacology*, **2009**, 78, 1419-27	6	66
121	The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. *Diabetologia*, **2009**, 52, 1143-51	10.3	303

120	Causal interpretation requires appropriate study design. Reply to Priest PC [letter]. *Diabetologia*, **2009**, 52, 1452-1453	10.3	
119	Islet-associated macrophages in type 2 diabetes. *Diabetologia*, **2009**, 52, 1686-8	10.3	161
118	Analysis of islet inflammation in human type 1 diabetes. *Clinical and Experimental Immunology*, **2009**, 155, 173-81	6.2	468
117	Fatty acids and beta-cell toxicity. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2009**, 12, 117-22	3.8	36
116	The incubation and monitoring of cell viability in primary rat islets of Langerhans and pancreatic beta-cell lines. *Methods in Molecular Biology*, **2009**, 560, 53-64	1.4	3
115	Structural requirements for the cytoprotective actions of mono-unsaturated fatty acids in the pancreatic beta-cell line, BRIN-BD11. *British Journal of Pharmacology*, **2008**, 153, 1718-27	8.6	31
114	The cytoprotective actions of long-chain mono-unsaturated fatty acids in pancreatic beta-cells. *Biochemical Society Transactions*, **2008**, 36, 905-8	5.1	37
113	Differential regulation of the endoplasmic reticulum stress response in pancreatic beta-cells exposed to long-chain saturated and monounsaturated fatty acids. *Journal of Endocrinology*, **2008**, 197, 553-63	4.7	95
112	The protein tyrosine phosphatase-BL, modulates pancreatic beta-cell proliferation by interaction with the Wnt signalling pathway. *Journal of Endocrinology*, **2008**, 197, 543-52	4.7	20
111	Differential regulation of the ER stress response by long-chain fatty acids in the pancreatic beta-cell. *Biochemical Society Transactions*, **2008**, 36, 959-62	5.1	37
110	Preparation of analogues of efaroxan and KU14R as potential imidazoline receptor subtype 3 ligands. *Journal of Heterocyclic Chemistry*, **2008**, 45, 887-896	1.9	4
109	Inhalation of glutamic acid decarboxylase 65-derived peptides can protect against recurrent autoimmune but not alloimmune responses in the non-obese diabetic mouse. *Clinical and Experimental Immunology*, **2007**, 148, 368-72	6.2	6
108	Pre-incubation with interleukin-4 mediates a direct protective effect against the loss of pancreatic beta-cell viability induced by proinflammatory cytokines. *Clinical and Experimental Immunology*, **2007**, 148, 583-8	6.2	14
107	Mechanisms involved in the cytotoxic and cytoprotective actions of saturated versus monounsaturated long-chain fatty acids in pancreatic beta-cells. *Journal of Endocrinology*, **2007**, 194, 283-91	4.7	58
106	Life and death decisions of the pancreatic beta-cell: the role of fatty acids. *Clinical Science*, **2007**, 112, 27-42	6.5	119
105	Conditional expression of hepatocyte nuclear factor-1beta, the maturity-onset diabetes of the young-5 gene product, influences the viability and functional competence of pancreatic beta-cells. *Journal of Endocrinology*, **2006**, 190, 171-81	4.7	18
104	A Kir6.2 mutation causing neonatal diabetes impairs electrical activity and insulin secretion from INS-1 beta-cells. *Diabetes*, **2006**, 55, 3075-82	0.9	37
103	Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. *Human Molecular Genetics*, **2006**, 15, 2216-24	5.6	100

102	Rhes expression in pancreatic beta-cells is regulated by efaroxan in a calcium-dependent process. *Biochemical and Biophysical Research Communications*, **2006**, 349, 809-15	3.4	4
101	Differential protective effects of palmitoleic acid and cAMP on caspase activation and cell viability in pancreatic beta-cells exposed to palmitate. *Apoptosis: an International Journal on Programmed Cell Death*, **2006**, 11, 1231-8	5.4	43
100	Imidazoleacetic acid-ribotide: an endogenous ligand that stimulates imidazol(in)e receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 13677-82	11.5	31
99	Evidence that protein kinase Cdelta is not required for palmitate-induced cytotoxicity in BRIN-BD11 beta-cells. *Journal of Molecular Endocrinology*, **2004**, 32, 227-35	4.5	19
98	Expression and functional activity of PPARgamma in pancreatic beta cells. *British Journal of Pharmacology*, **2004**, 142, 1162-70	8.6	25
97	The putative imidazoline receptor agonist, harmane, promotes intracellular calcium mobilisation in pancreatic beta-cells. *European Journal of Pharmacology*, **2004**, 501, 31-9	5.3	12
96	Phosphorylcholine-containing polymers for use in cell encapsulation. *Artificial Cells, Blood Substitutes, and Biotechnology*, **2004**, 32, 91-104		7
95	Involvement of the cGMP signalling pathway in the regulation of viability in insulin-secreting BRIN-BD11 cells. *FEBS Letters*, **2004**, 559, 118-24	3.8	14
94	Mono-unsaturated fatty acids protect against beta-cell apoptosis induced by saturated fatty acids, serum withdrawal or cytokine exposure. *FEBS Letters*, **2004**, 560, 103-8	3.8	77
93	Comparative effects of efaroxan and beta-carbolines on the secretory activity of rodent and human beta cells. *Annals of the New York Academy of Sciences*, **2003**, 1009, 167-74	6.5	13
92	Effects of the beta-carbolines, harmane and pinoline, on insulin secretion from isolated human islets of Langerhans. *European Journal of Pharmacology*, **2003**, 482, 189-96	5.3	35
91	Functional effects of expression of wolframin-antisense transcripts in BRIN-BD11 beta-cells. *Biochemical and Biophysical Research Communications*, **2003**, 307, 684-8	3.4	8
90	GTP-binding proteins in cell survival and demise: the emerging picture in the pancreatic beta-cell. *Biochemical Pharmacology*, **2002**, 63, 1027-35	6	18
89	Identification of the monomeric G-protein, Rhes, as an efaroxan-regulated protein in the pancreatic beta-cell. *British Journal of Pharmacology*, **2002**, 136, 31-6	8.6	12
88	Differential effects of genistein on apoptosis induced by fluoride and pertussis toxin in human and rat pancreatic islets and RINm5F cells. *Journal of Endocrinology*, **2002**, 172, 137-43	4.7	22
87	Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus. *Clinical and Experimental Immunology*, **2001**, 126, 242-9	6.2	49
86	Preparation of novel 2-(benzo[b]furan-2-yl)-1H-imidazolines for photoaffinity labelling and affinity isolation of imidazoline binding. *Journal of Heterocyclic Chemistry*, **2001**, 38, 519-521	1.9	4
85	Effects of tyrosine kinase inhibitors on cell death induced by sodium fluoride and pertussis toxin in the pancreatic beta-cell line, RINm5F. *British Journal of Pharmacology*, **2001**, 132, 119-26	8.6	15

84	Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. *Diabetes*, **2001**, 50, 340-7	0.9	32
83	Preparation of the I3 Imidazoline Receptor Antagonist KU14R and Related 2,3-Dihydrobenzo[b]furan Derivatives. *Synthesis*, **2001**, 2001, 1546	2.9	4
82	Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?. *Current Pharmaceutical Design*, **2001**, 7, 1413-31	3.3	61
81	Dissociation between Fas expression and induction of apoptosis in human islets of Langerhans. *Diabetes, Obesity and Metabolism*, **2000**, 2, 57-60	6.7	6
80	Effects of imidazoline binding site ligands on the growth and viability of clonal pancreatic beta-cells. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2000**, 361, 146-54	3.4	3
79	Imidazolines and pancreatic hormone secretion. *Annals of the New York Academy of Sciences*, **1999**, 881, 217-28	6.5	62
78	Multiple effector pathways regulate the insulin secretory response to the imidazoline RX871024 in isolated rat pancreatic islets. *British Journal of Pharmacology*, **1999**, 127, 1279-87	8.6	12
77	Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats. *European Journal of Pharmacology*, **1999**, 377, 81-7	5.3	6
76	Extraction of active clonidine-displacing substance from bovine lung and comparison with clonidine-displacing substance extracted from other tissues. *European Journal of Pharmacology*, **1999**, 378, 213-21	5.3	11
75	Characterization of monoamine oxidase isoforms in human islets of Langerhans. *Life Sciences*, **1999**, 65, 441-8	6.8	9
74	Affinity isolation of imidazoline binding proteins from rat brain using 5-amino-efaroxan as a ligand. *FEBS Letters*, **1999**, 447, 61-4	3.8	22
73	Imidazoline receptors: new targets for antihyperglycaemic drugs. *Expert Opinion on Investigational Drugs*, **1999**, 8, 575-84	5.9	23
72	Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites. *European Journal of Pharmacology*, **1998**, 355, 67-76	5.3	21
71	Activation of protein kinase C modulates alpha2-adrenergic signalling in rat pancreatic islets. *Cellular Signalling*, **1998**, 10, 637-43	4.9	14
70	'Seeing through a glass darkly?' casting light on imidazoline 'I'-sites. *Trends in Pharmacological Sciences*, **1998**, 19, 381-90	13.2	232
69	Effector systems involved in the insulin secretory responses to efaroxan and RX871024 in rat islets of Langerhans. *European Journal of Pharmacology*, **1998**, 350, 251-8	5.3	9
68	Sigma receptor ligands and imidazoline secretagogues mediate their insulin secretory effects by activating distinct receptor systems in isolated islets. *European Journal of Pharmacology*, **1998**, 350, 267-72	5.3	14
67	Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-1beta and Fas ligation. *Diabetes*, **1998**, 47, 727-32	0.9	132

66	Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with sigma receptors. *European Journal of Pharmacology*, **1997**, 323, 241-4	5.3	17
65	Insulin secretagogues with an imidazoline structure inhibit arginine-induced secretion from isolated glucagon secretion from isolated rat islets of Langerhans. *Biochemical and Biophysical Research Communications*, **1997**, 236, 162-6	3.4	10
64	Evidence for the involvement of cGMP and protein kinase G in nitric oxide-induced apoptosis in the pancreatic B-cell line, HIT-T15. *FEBS Letters*, **1997**, 400, 285-8	3.8	83
63	The effect of the putative endogenous imidazoline receptor ligand, clonidine-displacing substance, on insulin secretion from rat and human islets of Langerhans. *British Journal of Pharmacology*, **1997**, 120, 926-32	8.6	25
62	Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion. *British Journal of Pharmacology*, **1997**, 121, 799-805	8.6	12
61	Differential expression of alpha 2-adrenoceptor subtypes in purified rat pancreatic islet A- and B-cells. *Cellular Signalling*, **1997**, 9, 71-8	4.9	32
60	Superoxide, nitric oxide, peroxynitrite and cytokine combinations all cause functional impairment and morphological changes in rat islets of Langerhans and insulin secreting cell lines, but dictate cell death by different mechanisms. *Apoptosis: an International Journal on Programmed Cell Death*, **1997**, 2, 164-77	5.4	42
59	Clotrimazole and efaroxan stimulate insulin secretion by different mechanisms in rat pancreatic islets. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1997**, 356, 763-8	3.4	11
58	Identification and characterization of non-adrenergic binding sites in insulin-secreting cells with the imidazoline RX821002. *Advances in Experimental Medicine and Biology*, **1997**, 426, 159-63	3.6	2
57	Immunological analysis of G-protein expression in the endocrine pancreas. *Advances in Experimental Medicine and Biology*, **1997**, 426, 81-4	3.6	
56	Heterotrimeric G-proteins are implicated in the regulation of apoptosis in pancreatic beta-cells. *Experimental Cell Research*, **1996**, 229, 69-76	4.2	37
55	A specific inhibitor of cytosolic phospholipase A2 activity, AACOCF3, inhibits glucose-induced insulin secretion from isolated rat islets. *Biochemical and Biophysical Research Communications*, **1996**, 218, 423-7	3.4	30
54	Expression of alpha 2- and beta-adrenoceptor subtypes in human islets of Langerhans. *Journal of Endocrinology*, **1996**, 148, 531-43	4.7	30
53	Phospholipase A2 expression in human and rodent insulin-secreting cells. *Molecular and Cellular Endocrinology*, **1995**, 112, 177-83	4.4	23
52	The imidazoline I1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans. *European Journal of Pharmacology*, **1995**, 284, 199-203	5.3	11
51	Pancreatic beta-cells express an imidazoline binding site that is distinct from I1 and I2 sites. *Annals of the New York Academy of Sciences*, **1995**, 763, 153-6	6.5	14
50	Characterization of the imidazoline binding site involved in regulation of insulin secretion. *Annals of the New York Academy of Sciences*, **1995**, 763, 361-73	6.5	37
49	Activation of alpha-2-adrenoceptors results in an increase in F-actin formation in HIT-T15 pancreatic B-cells. *Biochemical Journal*, **1995**, 307 (Pt 1), 169-74	3.8	20

48	Treatment of cultured pancreatic B-cells with streptozotocin induces cell death by apoptosis. *Bioscience Reports*, **1994**, 14, 243-50	4.1	47
47	The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites. *British Journal of Pharmacology*, **1994**, 112, 1065-70	8.6	88
46	A comparison of cytosolic phospholipase A2 expression in human islets of Langerhans and rodent insulin-secreting cells. *Biochemical Society Transactions*, **1994**, 22, 430S	5.1	4
45	Section Review: Oncologic, Endocrine and Metabolic Adrenoceptors and imidazoline binding sites in the endocrine pancreas as targets for anti-hyperglycaemic drugs. *Expert Opinion on Investigational Drugs*, **1994**, 3, 561-569	5.9	5
44	Stimulation of insulin secretion by the imidazoline alpha 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site. *European Journal of Pharmacology*, **1993**, 230, 375-8	5.3	45
43	Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites. *British Journal of Pharmacology*, **1993**, 108, 312-7	8.6	38
42	Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080. *British Journal of Pharmacology*, **1993**, 110, 1017-22	8.6	58
41	Concentration-dependent effects of adrenaline on the profile of insulin secretion from isolated human islets of Langerhans. *Journal of Endocrinology*, **1993**, 138, 555-63	4.7	33
40	Control of insulin secretion by imidazolines in rat pancreatic islets. *Biochemical Society Transactions*, **1993**, 21, 109S	5.1	1
39	Immunological characterization of the guanine-nucleotide binding proteins Gi and Go in rat islets of Langerhans. *Journal of Molecular Endocrinology*, **1992**, 8, 103-8	4.5	19
38	Evidence that the presence of arginine can lead to overestimation of glucagon levels measured by radioimmunoassay. *Clinica Chimica Acta*, **1992**, 210, 211-9	6.2	
37	Immunoprecipitation of a pertussis toxin substrate of the G(o) family from rat islets of Langerhans. *Bioscience Reports*, **1992**, 12, 95-100	4.1	2
36	Selective stimulation of glucagon secretion by beta 2-adrenoceptors in isolated islets of Langerhans of the rat. *British Journal of Pharmacology*, **1991**, 103, 1824-8	8.6	17
35	Mechanisms involved in stimulation of insulin secretion by the hypoglycaemic alpha-adrenergic antagonist, DG-5128. *Biochemical and Biophysical Research Communications*, **1991**, 176, 1545-51	3.4	21
34	The alpha 2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells. *European Journal of Pharmacology*, **1991**, 204, 41-8	5.3	84
33	Differential effects of beta-adrenergic agonists on insulin secretion from pancreatic islets isolated from rat and man. *Journal of Molecular Endocrinology*, **1990**, 5, 49-54	4.5	28
32	Evidence for the presence of low molecular mass GTP-binding proteins in rat islets of Langerhans. *Biochemical Society Transactions*, **1990**, 18, 485-6	5.1	4
31	Evidence for differential effects of noradrenaline and somatostatin on intracellular messenger systems in rat islets of Langerhans. *Journal of Molecular Endocrinology*, **1990**, 4, 231-7	4.5	17

30	Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. *European Journal of Pharmacology*, **1990**, 176, 97-101	5.3	76
29	Effects of benextramine on the adrenergic inhibition of insulin secretion in isolated rat pancreatic islets. *Journal of Molecular Endocrinology*, **1989**, 2, 99-105	4.5	2
28	Effects of phenoxybenzamine on insulin secretion from isolated rat islets of Langerhans. *Bioscience Reports*, **1989**, 9, 223-30	4.1	1
27	Calcium handling by stimulated islets of Langerhans. *Biochemical Society Transactions*, **1989**, 17, 64-6	5.1	
26	Intracellular events responsible for the inhibition of insulin secretion by somatostatin. *Biochemical Society Transactions*, **1989**, 17, 1085-6	5.1	2
25	Dissociation between intracellular calcium mobilization and insulin secretion in isolated rat islets of Langerhans. *FEBS Letters*, **1988**, 227, 153-6	3.8	2
24	Effects of □adrenergic antagonists on insulin secretion from rat pancreatic islets. *Biochemical Society Transactions*, **1988**, 16, 1005-1006	5.1	13
23	Mechanisms involved in intracellular calcium mobilization in isolated rat islets of Langerhans. *Biochemical Journal*, **1987**, 244, 669-74	3.8	8
22	Intracellular Ca2+ mobilization in isolated rat islets of Langerhans. *Biochemical Society Transactions*, **1987**, 15, 939-940	5.1	
21	Regulation of insulin secretion by □-adrenergic agonists. *Trends in Pharmacological Sciences*, **1987**, 8, 369-370	13.2	21
20	Mechanisms involved in the □-adrenergic inhibition of insulin secretion. *Biochemical Society Transactions*, **1986**, 14, 1019-1020	5.1	1
19	Studies on the mechanism of inhibition of glucose-stimulated insulin secretion by noradrenaline in rat islets of Langerhans. *Biochemical Journal*, **1985**, 226, 571-6	3.8	67
18	Effect of glucose on polyphosphoinositide metabolism in isolated rat islets of Langerhans. *Biochemical Journal*, **1985**, 227, 483-9	3.8	66
17	Studies on the role of inositol trisphosphate in the regulation of insulin secretion from isolated rat islets of Langerhans. *Biochemical Journal*, **1985**, 228, 713-8	3.8	61
16	Effects of the calcium-channel agonist CGP 28392 on insulin secretion from isolated rat islets of Langerhans. *Biochemical Journal*, **1985**, 231, 629-34	3.8	13
15	Cyclic AMP-dependent modulation of □-adrenergic responses in rat liver. *Biochemical Society Transactions*, **1985**, 13, 217-218	5.1	3
14	Effects of noradrenaline on 45Ca2+ efflux from isolated rat islets of Langerhans. *Bioscience Reports* , **1985**, 5, 1053-60	4.1	7
13	Studies on the mechanism by which melittin stimulates insulin secretion from isolated rat islets of Langerhans. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1985**, 845, 526-32	4.9	15

12	Stimulation of insulin secretion from isolated rat islets of Langerhans by melittin. *Bioscience Reports*, **1984**, 4, 665-71	4.1	31
11	Potentiation of alpha 1-adrenergic responses in rat liver by a cAMP-dependent mechanism. *Proceedings of the National Academy of Sciences of the United States of America*, **1984**, 81, 4208-12	11.5	57
10	Angiotensin II inhibits hepatic cAMP accumulation induced by glucagon and epinephrine and their metabolic effects. *FEBS Letters*, **1983**, 153, 77-80	3.8	22
9	Studies on the mechanism of inhibition of hepatic cAMP accumulation by vasopressin. *FEBS Letters*, **1983**, 163, 277-81	3.8	25
8	Characterisation of the alpha 1-adrenergic control of hepatic cAMP in male rats. *European Journal of Pharmacology*, **1983**, 96, 1-10	5.3	29
7	Age-related changes in the control of hepatic cyclic AMP levels by alpha 1- and beta 2-adrenergic receptors in male rats. *Journal of Biological Chemistry*, **1983**, 258, 5103-9	5.4	111
6	Modulation of the alpha 1-adrenergic control of hepatocyte calcium redistribution by increases in cyclic AMP. *Journal of Biological Chemistry*, **1983**, 258, 5110-6	5.4	57
5	Studies on the interaction of staphylococcal delta-haemolysin with isolated islets of Langerhans. *Biochemical Journal*, **1982**, 204, 111-25	3.8	6
4	Stimulation of hepatic glycogenolysis by alpha 1- and beta 2-adrenergic agonists. Evidence against short term agonist-induced desensitization of the responses. *Journal of Biological Chemistry*, **1982**, 257, 13907-10	5.4	36
3	The effect of staphylococcal delta-haemolysin on the secretory activity of the pancreatic beta-cell. *Bioscience Reports*, **1981**, 1, 135-40	4.1	1
2	Subcellular distribution of protein kinase activities in mammalian islets of Langerhans [proceedings]. *Biochemical Society Transactions*, **1979**, 7, 913-5	5.1	
1	Detection of enterovirus protein and RNA in multiple tissues from nPOD organ donors with type 1 diabetes		5